These data suggest that the newly identified E6.5 signature captures a distinct gene expression pattern that is independently indicative of tumor recurrence and/or distant metastasis among a wide array of breast cancer patients - luminal A, -B, -C, ER+/−, PR+/−, Her2+/−, basal and grade I, II or III tumors. Here, ERBB2 is linked to breast carcinoma.